Assessed for eligibility (n = 294)

Excluded n = 12
- Did not receive at least one dose of study medication n = 12

Received treatment with IV anidulafungin n = 282

Discontinuations n = 122
- Patient died n = 43
- Related to study drug n = 4
- Unrelated to study drug n = 75

Analyzed:
Full analysis set n = 282
- Excluded n = 32
  - No positive baseline culture n = 32
MITT population n = 250
- Switched to oral azole therapy n = 150
  - Voriconazole n = 52*
  - Fluconazole n = 99*
- Early switch subpopulation n = 102
- Remained on IV anidulafungin n = 100

Completed study n = 160

*Two patients received both oral fluconazole and oral voriconazole. Abbreviations used: IV, intravenous; MITT, modified intent-to-treat.